stockrow
Saturday 7 November 2026
Export PGEN’s income statement to Excel — free account
Precigen, Inc.
PGEN Healthcare Biotechnology
Precigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024.
- Revenue
- +2,437.6%
- EPS
- +109.4%
- Free cash flow
- +140.3%
- Total debt
- +1.47%
Quarter to September 2026, against a year earlier
4.43
0.21
+4.98%
Follow PGEN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 116.46 |
P/S ratio |
135.09 | 43.40 | 23.73 | 19.54 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(55.77) | (31.28) | (114.23) | 258.07 | |
P/B ratio |
62.56 | 67.76 | 46.68 | 36.60 | |
Price to Tangible BV |
523.91 | 641.00 | 78.85 | 46.23 | |
EV/Sales |
136.04 | 45.01 | 24.54 | 19.93 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 82.36 | |
EV/Operating CF |
(15.00) | (12.33) | (18.43) | (42.73) | |
EV/FCF |
(14.67) | (12.16) | (18.26) | (42.10) | |
Quick Ratio |
2.74 | 3.93 | 3.76 | 4.63 | |
Current Ratio |
3.09 | 4.82 | 4.58 | 5.58 | |
Net Debt/EBITDA |
0.22 | (7.58) | 2.33 | 1.21 | |
Debt/Assets |
59.92% | 67.46% | 55.13% | 44.44% | |
Debt/Equity |
4.46 | 4.62 | 2.15 | 1.12 | |
Asset Turnover |
0.06 | 0.24 | 0.63 | 0.82 | |
Operating CF/Net income |
1.00 | 5.53 | (0.89) | 0.33 | |
Capex/Depreciation |
(0.03) | (0.24) | (0.31) | (0.33) | |
Interest Coverage |
(7.31) | (2.06) | 7.67 | 12.90 | |
Research and Development Expense of Revenue |
153.12% | 24.25% | 13.25% | 8.94% | |
Selling, General and Administrative Expense of Revenue |
386.53% | 90.53% | 40.47% | 30.15% | |
Intangible Assets out of Total Assets |
0.12 | 0.13 | 0.10 | 0.08 | |
Share Based Compensation of Revenue |
47.38% | 15.19% | 6.51% | 5.09% | |
Graham Net Nets |
(0.01) | (0.01) | 0.00 | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.62 | |
Earnings Yield |
(33.40%) | (31.95%) | (19.06%) | 0.86% | |
Free Cash Flow Yield |
(6.87%) | (8.53%) | (5.66%) | (2.42%) | |
Revenue per Share |
0.01 | 0.07 | 0.15 | 0.21 | |
Operating CF per Share |
(0.07) | (0.12) | (0.05) | 0.03 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.12) | (0.05) | 0.03 | |
Cash per Share |
0.31 | 0.16 | 0.11 | 0.13 | |
Shareholders Equity per Share |
0.07 | 0.06 | 0.12 | 0.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.07 | 0.06 | 0.12 | 0.23 | |
Free Cash Flow |
(23.48) | (44.08) | (18.20) | 11.45 | |
Working Capital |
77.93 | 80.57 | 105.03 | 140.97 | |
Capital Expenditures |
(0.02) | (0.26) | (0.39) | (0.43) | |
Net Current Asset Value |
(19.36) | (16.72) | 7.66 | 43.45 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 93.03 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 91.18 | |
| Other line items | |||||
Average Receivables |
2.76 | 13.88 | 36.31 | 48.86 | |
Average Payables |
7.76 | 2.85 | 4.61 | 6.66 | |
Average Inventory |
4.90 | 7.47 | 10.27 | 12.99 | |
Average Assets |
150.39 | 133.71 | 136.10 | 191.68 | |
Average Common Equity |
29.71 | 3.09 | 3.40 | 62.83 |
Columns are period end dates · fundamentals updated 6 Nov 2026